Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

SARS-CoV-2 spike antibody concentration in gamma globulin products from high-prevalence COVID-19 countries are transmitted to X-linked agammaglobulinemia patients

View through CrossRef
PurposePatients with X-linked agammaglobulinemia (XLA) are characterized by humoral impairment and are routinely treated with intravenous immunoglobulin (IVIG). In this study, we aimed to investigate the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in IVIG preparations harvested globally and evaluate the transfer of SARS-CoV-2 antibodies to the XLA patient.MethodsA single-center, prospective cohort study was conducted in the period of November 2020 to November 2022. Clinical and laboratory data, specifically, SARS-CoV-2 spike IgG levels from the serum of 115 IVIG preparations given to 5 XLA patient were collected. Concurrently, SARS-CoV-2 spike IgG levels from the serum of the 5 XLA was collected monthly.ResultsFive XLA patients were evaluated within the study period. All were treated monthly with commercial IVIG preparations. A total of 115 IVIG treatments were given over the study period. The origin country and the date of IVIG harvesting was obtained for 111 (96%) of the treatments. Fifty-four IVIG preparations (49%) were harvested during the COVID-19 pandemic of which 76% were positive (>50AU/mL) for SARS-CoV-2 spike antibodies which were subsequently transmitted to the XLA patients in an approximate 10-fold reduction. SARS-CoV2 spike IgG was first detected in IVIG batches that completed their harvest date by September 2021. Positive products were harvested from origin countries with a documented prevalence over 2,000 per 100,000 population.ConclusionAs the prevalence of COVID-19 infections rises, detection of SARS-CoV-2 spike IgG in commercial IVIG products increases and is then transmitted to the patient. Future studies are needed to investigate the neutralizing capabilities of SARS-CoV-2 IgG and whether titer levels in IVIG remain consistent as the incidence of infection and vaccination rates in the population changes.
Title: SARS-CoV-2 spike antibody concentration in gamma globulin products from high-prevalence COVID-19 countries are transmitted to X-linked agammaglobulinemia patients
Description:
PurposePatients with X-linked agammaglobulinemia (XLA) are characterized by humoral impairment and are routinely treated with intravenous immunoglobulin (IVIG).
In this study, we aimed to investigate the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in IVIG preparations harvested globally and evaluate the transfer of SARS-CoV-2 antibodies to the XLA patient.
MethodsA single-center, prospective cohort study was conducted in the period of November 2020 to November 2022.
Clinical and laboratory data, specifically, SARS-CoV-2 spike IgG levels from the serum of 115 IVIG preparations given to 5 XLA patient were collected.
Concurrently, SARS-CoV-2 spike IgG levels from the serum of the 5 XLA was collected monthly.
ResultsFive XLA patients were evaluated within the study period.
All were treated monthly with commercial IVIG preparations.
A total of 115 IVIG treatments were given over the study period.
The origin country and the date of IVIG harvesting was obtained for 111 (96%) of the treatments.
Fifty-four IVIG preparations (49%) were harvested during the COVID-19 pandemic of which 76% were positive (>50AU/mL) for SARS-CoV-2 spike antibodies which were subsequently transmitted to the XLA patients in an approximate 10-fold reduction.
SARS-CoV2 spike IgG was first detected in IVIG batches that completed their harvest date by September 2021.
Positive products were harvested from origin countries with a documented prevalence over 2,000 per 100,000 population.
ConclusionAs the prevalence of COVID-19 infections rises, detection of SARS-CoV-2 spike IgG in commercial IVIG products increases and is then transmitted to the patient.
Future studies are needed to investigate the neutralizing capabilities of SARS-CoV-2 IgG and whether titer levels in IVIG remain consistent as the incidence of infection and vaccination rates in the population changes.

Related Results

The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract Introduction Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus , is causing a serious worldwide COVID-19 pandemic. The emergence of strains with rapid spread and...
KECEMASAN SAAT PANDEMI COVID 19: LITERATUR REVIEW Hardiyati, Efri Widianti, Taty Hernawaty Departemen Keperawatan Jiwa Poltekkes Kemenkes Mamuju Sulbar, Universitas Pad...
Analyses of the Spike Proteins of Severe Acute Respiratory Syndrome-Related Coronaviruses
Analyses of the Spike Proteins of Severe Acute Respiratory Syndrome-Related Coronaviruses
Aim: To analyze spike proteins of Severe Acute Respiratory Syndrome (SARS)-related coronaviruses (CoVs) for their conserved motifs, Receptor-BindingĀ  Domain (RBD), Receptor Binding...
Mutations in SARS-CoV
Mutations in SARS-CoV
The coronavirus family is named for the large spike protein molecules found on the pathogen exterior, which give the virus a crown-like appearance, the coronavirus genome is the bi...
Modeling Coronavirus Spike Protein Dynamics: Implications for Immunogenicity and Immune Escape
Modeling Coronavirus Spike Protein Dynamics: Implications for Immunogenicity and Immune Escape
ABSTRACT The ongoing COVID-19 pandemic is a global public health emergency requiring urgent development of efficacious vaccines. While concentrated research efforts...

Back to Top